Keratoacanthoma

Revision as of 15:11, 11 August 2014 by Kiran Singh (talk | contribs) (→‎Face)
Jump to navigation Jump to search

WikiDoc Resources for Keratoacanthoma

Articles

Most recent articles on Keratoacanthoma

Most cited articles on Keratoacanthoma

Review articles on Keratoacanthoma

Articles on Keratoacanthoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Keratoacanthoma

Images of Keratoacanthoma

Photos of Keratoacanthoma

Podcasts & MP3s on Keratoacanthoma

Videos on Keratoacanthoma

Evidence Based Medicine

Cochrane Collaboration on Keratoacanthoma

Bandolier on Keratoacanthoma

TRIP on Keratoacanthoma

Clinical Trials

Ongoing Trials on Keratoacanthoma at Clinical Trials.gov

Trial results on Keratoacanthoma

Clinical Trials on Keratoacanthoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Keratoacanthoma

NICE Guidance on Keratoacanthoma

NHS PRODIGY Guidance

FDA on Keratoacanthoma

CDC on Keratoacanthoma

Books

Books on Keratoacanthoma

News

Keratoacanthoma in the news

Be alerted to news on Keratoacanthoma

News trends on Keratoacanthoma

Commentary

Blogs on Keratoacanthoma

Definitions

Definitions of Keratoacanthoma

Patient Resources / Community

Patient resources on Keratoacanthoma

Discussion groups on Keratoacanthoma

Patient Handouts on Keratoacanthoma

Directions to Hospitals Treating Keratoacanthoma

Risk calculators and risk factors for Keratoacanthoma

Healthcare Provider Resources

Symptoms of Keratoacanthoma

Causes & Risk Factors for Keratoacanthoma

Diagnostic studies for Keratoacanthoma

Treatment of Keratoacanthoma

Continuing Medical Education (CME)

CME Programs on Keratoacanthoma

International

Keratoacanthoma en Espanol

Keratoacanthoma en Francais

Business

Keratoacanthoma in the Marketplace

Patents on Keratoacanthoma

Experimental / Informatics

List of terms related to Keratoacanthoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Keratoacanthoma (KA) is a relatively common, benign, epithelial tumor that was previously considered to be a variant of squamous cell carcinoma (SCC). The etiology is unknown. No human papillomavirus-DNA sequences were detected in lesions by polymerase chain reaction. It is a disease of the elderly (mean age, 64 years) with an annual incidence rate of 104 per 100,000. It is not associated with internal malignancy. There may be a seasonal presentation of keratoacanthoma that suggests that ultraviolet radiation has an acute effect on the development of KA. KAs may develop in sites of previous trauma. Most cases are the “crateriform” type, which grow rapidly then undergo spontaneous regression. Less than 2% belong to the rare destructive variants with no regression and persistent invasive growth. These are referred to as keratoacanthoma marginatum centrifugum and mutilating keratoacanthomas and can lead to severe defects.

KA begins as a smooth, dome-shaped, red papule that resembles molluscum contagiosum. In a few weeks the tumor may rapidly expand to 1 or 2cm and develop a central keratin-filled crater that is frequently filled with crust. The growth retains its smooth surface, unlike a squamous cell carcinoma. Untreated, growth stops in approximately 6 weeks, and the tumor remains unchanged for an indefinite period. In the majority of cases it then regresses slowly over 2 to 12 months and frequently heals with scarring. The limbs, particularly the sun-exposed hands and arms, are the most common site; the trunk is the second most common site, but KA may occur on any skin surface, including the anal area. On occasion, multiple KAs appear, or a single lesion extends over several centimeters. These variants resist treatment and are unlikely to undergo spontaneous emission.

According to a review of literature by Robert A. Schwartz, KA was once considered a benign neoplasm that resembled a highly malignant one (pseudomalignancy), but it is now viewed in an opposite light as a cancer that resembles a benign neoplasm (pseudobenignity). KA is an abortive malignancy that rarely progresses into an invasive SCC. The KA may serve as a marker for the important autosomal dominant familial cancer syndrome, the Muir-Torre syndrome, as a result of a defective DNA mismatch repair gene.[2]

External links



Diagnosis

PhysicalExamination

Skin

Face
Extremities
Ear
Scalp

Template:WikiDoc Sources

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 1.27 1.28 1.29 1.30 1.31 1.32 1.33 1.34 1.35 1.36 1.37 1.38 1.39 1.40 "Dermatology Atlas".